1文献来源Vansteenkiste JF,Cho BC,Vanakesa T,et al.Efficacy of the MAGE-A3 cancer immunotherapeutic as adjuvant therapy in patients with resected MAGE-A3-positive non-small-cell lung cancer(MAGRIT):A randomised,double-...1文献来源Vansteenkiste JF,Cho BC,Vanakesa T,et al.Efficacy of the MAGE-A3 cancer immunotherapeutic as adjuvant therapy in patients with resected MAGE-A3-positive non-small-cell lung cancer(MAGRIT):A randomised,double-blind,placebo-controlled,phase 3 trial[J].Lancet Oncol,2016,17(6):822-835.2证据水平1b。3背景?在完全切除的非小细胞肺癌(non-small cell lung cancer,NSCLC)患者中,只有不到一半的患者被治愈,而其他患者的癌症复发通常是致命的。在过去的几十年里,已研究了几种辅助治疗方法来改善这些患者的预后。?目前发现MAGE-A3是肿瘤组织表达最多的肿瘤-睾丸抗原(cancer-testis antigen,CTA)之一,被认为是真正的肿瘤特异性抗原,在许多肿瘤中表达,例如恶性黑色素瘤、肺癌、头颈部肿瘤、肝细胞癌等。30%~50%的NSCLC存在MAGE-A3表达,其中鳞癌(48%)比非鳞癌(24%)比例更高。而对于可切除的NSCLC,只有不到一半的患者达到临床治愈,更多的患者会出现肿瘤复发。传统的辅助化疗无法提供更多的临床获益,针对MAGE-A3抗原的肺癌疫苗对术后患者体内残存的癌细胞可能具有一定的治疗潜力。展开更多
Objective： To inwvetigate the expression of MAGE-A3 mRNA in tissue samples derived from lung cancers and to discuss the possibility of using MAGE-A3 antigens as a new peptide vaccine for inunotherapy for lung cancers...Objective： To inwvetigate the expression of MAGE-A3 mRNA in tissue samples derived from lung cancers and to discuss the possibility of using MAGE-A3 antigens as a new peptide vaccine for inunotherapy for lung cancers. Methods： Tumor tissue samples of lung cancers and paired non-tumor tissues of the lung were obtaimed from 31 lung cancer patients. Total RNA was extracted and cDNA was synthesized. Nested polymernse chain reaction amplification using MAGE-A3 specific primer was performed to detect the expression of MAGE-A3. The 10 clones of 5 samples of MAGE-A3 mRNA positive PCR products were DNA sequenced by using DNAs sequencer （PE-377）. Results： Of 31 lung cancers, 26 （83.9%） expressed MACE-A3 mRNA. The expression of MAGE-A3 gene was not detectable in the adjacent lung tissues. The DNA sequencing confirmed that the target gene fragment in all 5 samples of PCR products was MACE-A3 cDNA. Point nmtations occurred in 4 samples （8 clones） detected （C^2773→T^2773; G^2807→A^2807） resulting in alternation of amino acid residue in one position （E^143→K）. Conclusion： （1） The MAGE-A3 gene was expressed exclusively in tumor tissues of the patients with lung cancer in China. This tumor rejection antigen may have potential to be used as a new peptide vaccine for immunotherapy for lung eancers. （2） There are two point mutations of MAGE-A3 gene sequence in some Chinese lung cancer patients.展开更多
文摘1文献来源Vansteenkiste JF,Cho BC,Vanakesa T,et al.Efficacy of the MAGE-A3 cancer immunotherapeutic as adjuvant therapy in patients with resected MAGE-A3-positive non-small-cell lung cancer(MAGRIT):A randomised,double-blind,placebo-controlled,phase 3 trial[J].Lancet Oncol,2016,17(6):822-835.2证据水平1b。3背景?在完全切除的非小细胞肺癌(non-small cell lung cancer,NSCLC)患者中,只有不到一半的患者被治愈,而其他患者的癌症复发通常是致命的。在过去的几十年里,已研究了几种辅助治疗方法来改善这些患者的预后。?目前发现MAGE-A3是肿瘤组织表达最多的肿瘤-睾丸抗原(cancer-testis antigen,CTA)之一,被认为是真正的肿瘤特异性抗原,在许多肿瘤中表达,例如恶性黑色素瘤、肺癌、头颈部肿瘤、肝细胞癌等。30%~50%的NSCLC存在MAGE-A3表达,其中鳞癌(48%)比非鳞癌(24%)比例更高。而对于可切除的NSCLC,只有不到一半的患者达到临床治愈,更多的患者会出现肿瘤复发。传统的辅助化疗无法提供更多的临床获益,针对MAGE-A3抗原的肺癌疫苗对术后患者体内残存的癌细胞可能具有一定的治疗潜力。
基金This project was supported by the key project of Scientific Committee of Henan Province (No. 0124170232), the key project ofZhengzhou Scientific Committee (No. 04BA60ABYD18), and Tumor Biology Subproject of 211 project of zhengzhou Univevsity
文摘Objective： To inwvetigate the expression of MAGE-A3 mRNA in tissue samples derived from lung cancers and to discuss the possibility of using MAGE-A3 antigens as a new peptide vaccine for inunotherapy for lung cancers. Methods： Tumor tissue samples of lung cancers and paired non-tumor tissues of the lung were obtaimed from 31 lung cancer patients. Total RNA was extracted and cDNA was synthesized. Nested polymernse chain reaction amplification using MAGE-A3 specific primer was performed to detect the expression of MAGE-A3. The 10 clones of 5 samples of MAGE-A3 mRNA positive PCR products were DNA sequenced by using DNAs sequencer （PE-377）. Results： Of 31 lung cancers, 26 （83.9%） expressed MACE-A3 mRNA. The expression of MAGE-A3 gene was not detectable in the adjacent lung tissues. The DNA sequencing confirmed that the target gene fragment in all 5 samples of PCR products was MACE-A3 cDNA. Point nmtations occurred in 4 samples （8 clones） detected （C^2773→T^2773; G^2807→A^2807） resulting in alternation of amino acid residue in one position （E^143→K）. Conclusion： （1） The MAGE-A3 gene was expressed exclusively in tumor tissues of the patients with lung cancer in China. This tumor rejection antigen may have potential to be used as a new peptide vaccine for immunotherapy for lung eancers. （2） There are two point mutations of MAGE-A3 gene sequence in some Chinese lung cancer patients.
